Characteristics of the new progestogens in combination oral contraceptives.
This review details the characteristic features of three new progestogens which soon will be available in low-dose combination oral contraceptive agents in the United States. Available data suggest that desogestrel, gestodene, and norgestimate are extremely potent progestogens with few androgenic side effects. The smaller changes in lipids induced by these progestogens seem to confer some advantage to the use of preparations containing one of these agents. Whether this advantage is also present clinically remains to be determined.
Rebar
R W
RW
University of Cincinnati Medical Center, Department of Obstetrics and Gynecology, Ohio 45267-0526.
Zeserson
K
K
D001777:Blood Coagulation / Q000187:drug effects; D050260:Carbohydrate Metabolism; D003277:Contraceptives, Oral, Combined; D017135:Desogestrel; D006801:Humans; D050356:Lipid Metabolism; D009644:Norgestrel / Q000031:analogs & derivatives / Q000494:pharmacology; D009652:Norpregnenes / Q000494:pharmacology; D045167:Progesterone Congeners / Q000494:pharmacology*
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D009644:Norgestrel; D017135:Desogestrel; C017576:norgestimate